Core Insights - The first version of the commercial insurance innovative drug directory has been released, including 19 new drugs from 18 innovative pharmaceutical companies, with a roughly equal share of domestic and imported drugs [1][2] - The directory focuses heavily on oncology drugs, which account for 70% of the list, including five CAR-T products, and also includes rare disease medications and Alzheimer's treatments [1][11] Summary by Category Drug Inclusion - A total of 121 drug generic names passed the review for the commercial insurance innovative drug directory, with only 19 drugs ultimately selected, resulting in an acceptance rate of approximately 16% [6] - The directory includes a variety of drugs, with a significant number targeting rare diseases and high-cost innovative treatments [12][14] Market Dynamics - The commercial insurance innovative drug directory is expected to enhance the payment space for rare disease treatments and provide policy advantages for hospital access [1][11] - The directory's limited number of drugs aims to facilitate implementation, as having too many drugs could complicate market entry [8][11] Drug Characteristics - The drugs in the directory generally have a small patient base or clear indications, minimizing the risk of clinical misuse, and are often high-value innovative drugs that fill clinical gaps [11][12] - The directory includes multiple oncology treatments, particularly those for rare or difficult-to-treat cancers, which are expected to have a significant market impact [12][13] Commercial Insurance Implications - The commercial insurance innovative drug directory serves as a reference for various commercial insurance entities, allowing them to negotiate with innovative drug companies without the need for exclusive selections [14] - The directory is anticipated to support the development of multi-tiered medical insurance systems, encouraging commercial insurance companies to design new products based on the directory [16]

Core Insights - The Chinese medical insurance directory will undergo its largest expansion of innovative drugs in history starting January 1, 2026, adding 114 new drugs, including 50 class 1 innovative drugs, while removing 29 drugs that are either unavailable or can be replaced by better alternatives [1][2] - The total number of drugs in the directory will increase to 3,253, significantly enhancing coverage for key areas such as oncology, chronic diseases, mental health, rare diseases, and pediatric medications [1][2] - The inclusion of innovative drugs in the medical insurance directory reflects a strong commitment to support genuine innovation and differentiated innovation in the healthcare sector [1][2] Medical Insurance Directory Expansion - The new directory will include 114 drugs, with nearly 44% being class 1 innovative drugs, indicating a growing emphasis on innovative treatments [1][2] - The directory will enhance the insurance coverage for critical areas, improving access to necessary medications for patients [1][2] Innovative Drug Market Dynamics - The entry of innovative drugs into the medical insurance directory is a key driver for market growth, with those included typically experiencing rapid sales growth within a year [4] - Companies like Heng Rui Medicine and Innovent Biologics have successfully included multiple innovative products in the new directory, indicating a trend towards increased market access for innovative therapies [4][5] Clinical Needs and Treatment Options - The new directory addresses significant clinical needs, particularly in oncology, with new drugs targeting various types of cancers, thereby expanding treatment options for patients [9][10] - The inclusion of targeted therapies for conditions like severe asthma and breast cancer provides patients with more accessible and effective treatment options [6][10] Commercial Insurance Directory - The introduction of a commercial insurance directory for innovative drugs aims to balance clinical value, corporate profits, and the sustainability of insurance funds [2][12] - The commercial insurance directory includes 19 innovative drugs, highlighting a focus on high-value treatments that exceed basic insurance coverage [12][15] Policy and Regulatory Environment - Recent reforms in drug approval and medical insurance payment systems have created a conducive environment for the development of innovative drugs in China [17][18] - The acceleration of drug approvals and the establishment of a more rigorous evaluation system for innovative drugs are reshaping the landscape for pharmaceutical companies [17][18] Future Outlook - The ongoing expansion of the medical insurance directory signifies a shift towards making innovative drugs more accessible and affordable for the general population, enhancing overall healthcare outcomes [20][21] - The collaboration between policy, industry, and capital markets is essential for fostering high-quality development in the innovative drug sector [19][20]

（原标题：吴清发表重要讲话；美联储将举行议息会议｜周末要闻速递） 要闻速递 国常会：研究进一步做好节能降碳工作 国务院总理李强12月5日主持召开国务院常务会议，研究进一步做好节能降碳工作，听取规范涉企行政 执法专项行动情况汇报并审议通过《行政执法监督条例（草案）》，讨论《中华人民共和国国家消防救 援人员法（草案）》，部署全链条打击涉烟违法活动有关举措。 李强将与全球主要国际经济组织负责人举行"1+10"对话会 外交部发言人宣布，国务院总理李强将于12月9日上午在北京同新开发银行行长罗塞芙、世界银行行长 彭安杰、国际货币基金组织总裁格奥尔基耶娃、世界贸易组织总干事伊维拉、联合国贸易和发展会议秘 书长格林斯潘、国际劳工组织总干事洪博、经济合作与发展组织秘书长科尔曼、国际清算银行总经理卡 斯滕斯、金融稳定理事会主席诺特和亚洲基础设施投资银行行长金立群等10家国际经济组织负责人举 行"1+10"对话会。 险企投资股票风险因子再度下调 沪深300、科创板等将受益 12月5日，国家金融监管总局发布《关于调整保险公司相关业务风险因子的通知》，在下调险企业务风 险因子的同时明确相关监管要求。一是对长期持仓的沪深300等指数成 ...

记者今天（7日）从国家医保局获悉，2025年国家医保药品目录及首版商保创新药目录在广东广州发 布。2025年国家医保药品目录成功新增114种药品，有50种是一类创新药，总体成功率88%，较2024年 的76%明显提高。19种药品纳入首版商保创新药目录。 此次调整后，国家医保药品目录内药品总数增至3253种，其中西药1857种、中成药1396种，肿瘤、慢性 病、精神疾病、罕见病、儿童用药等重点领域的保障水平得到明显提升。 国家医保局、人力资源社会保障部印发《国家基本医疗保险、生育保险和工伤保险药品目录》以及《商 业健康保险创新药品目录》（2025年）。其中提出，积极推动商保创新药目录纳入商业健康保险保障范 围。 各地医保部门要会同有关部门推动多层次医疗保障体系建设，积极支持普惠型商业健康保险发展，商保 创新药目录推荐商业健康保险、医疗互助等多层次医疗保障体系参考使用。支持商保机构根据商保创新 药目录设计新产品、更新赔付范围、调整赔付方式，更好满足患者用药需求，切实减轻患者医疗费用负 担。鼓励有条件的地区探索开展医保、工伤保险与商保"一站式"结算。 文章来源：央视新闻 2025年国家医保药品目录纳入了一些弥补基本 ...

中国基金报记者 王思文 【 导读 】 114种药品新增进入2025年国家医保药品目录，19种药品进入商保创新药目录 12月7日， 2025年药品目录谈判协商结果在广州发布，市场关注的新版基本医保药品目录和 首版《商业健康保险创新药品目录》正式公布。今年是国家医保药品目录连续第八年进行调 整。 新版药品目录自2026年1月1日起正式执行，《国家基本医疗保险、工伤保险和生育保险药品 目录（2024年）》（医保发〔2024〕33号）同时废止。 2025年版国家医保+商保药品目录正式发布 根据国家医保局对外发布的 2025年版国家基本医疗保险、生育保险和工伤保险药品目录和首 版商业健康保险创新药品目录 显示，2025年国家医保药品目录成功新增114种药品，19种药 品被纳入首版商保创新药目录。 在本次目录调整的新增药品中，有50种是一类创新药，总体成功率为88%，较2024年的 76%明显提高。 同时，一些弥补基本医保保障空白的药品被纳入2025年国家医保药品目录，如三阴性乳腺 癌、胰腺癌、肺癌等重大疾病用药；朗格汉斯细胞组织细胞增生症、螯合剂不耐受的地中海 贫血症等罕见病用药；糖尿病、高胆固醇血症、自身免疫性疾病等 ...

此次调整后，国家医保药品目录内药品总数增至3253种，其中西药1857种、中成药1396种，肿瘤、慢性 病、精神疾病、罕见病、儿童用药等重点领域的保障水平得到明显提升。 来源：央视新闻 （文章来源：证券时报） 2025年国家医保药品目录及首版商保创新药目录在广州发布。 2025年国家医保药品目录成功新增114种药品，有50种是一类创新药，总体成功率88%，较2024年的 76%明显提高。19种药品纳入首版商保创新药目录。 2025年国家医保药品目录纳入了一些弥补基本医保保障空白的药品，如三阴乳腺癌、胰腺癌、肺癌等重 大疾病用药；朗格汉斯细胞组织细胞增生症、螯合剂不耐受的地中海贫血症等罕见病用药；糖尿病、高 胆固醇血症、自身免疫性疾病等慢性病用药。 纳入首版商保创新药目录的19种药品中，既有CAR-T等肿瘤治疗药品，也有神经母细胞瘤、戈谢病等罕 见病治疗药品，还有阿尔茨海默病治疗药品等。 ...

Core Insights - The National Healthcare Security Administration (NHSA) has announced the 2025 version of the National Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance Drug Catalog, along with the first edition of the Commercial Health Insurance Innovative Drug Catalog. This marks the eighth consecutive year of adjustments to the drug catalog, which can be interpreted from three perspectives: new drugs, new partners, and new mechanisms [1] Group 1: New Drugs - A total of 114 new drugs have been added to the catalog, enhancing the coverage for critical areas such as cancer and chronic diseases. Among these, 111 are new products launched within the last five years, accounting for 97.3% of the additions [2] - The new drugs address clinical treatment gaps, including innovative therapies for major diseases like breast cancer, pancreatic cancer, and lung cancer, as well as medications for rare diseases and chronic conditions such as diabetes and high cholesterol [2][3] Group 2: New Partners - The recent innovative drug high-quality development conference included a diverse range of participants, such as investors, fund managers, and representatives from commercial insurance institutions, alongside traditional stakeholders like the NHSA and pharmaceutical companies. This indicates a growing recognition of the importance of innovation in healthcare [4] - The involvement of new partners reflects the understanding that healthcare is both a public welfare issue and an industry, highlighting the ongoing interest and investment from the capital market in pharmaceutical innovation [4] Group 3: New Mechanisms - The commercial insurance innovative drug catalog was released simultaneously with the basic medical insurance drug catalog. This addresses the ongoing debate regarding the inclusion of high-cost drugs in basic insurance coverage [5] - A total of 121 drugs met the criteria for the commercial insurance innovative drug catalog, with 19 ultimately included. This catalog features advanced treatment methods such as CAR-T and T-cell therapies, as well as medications for rare diseases and Alzheimer's, complementing the basic insurance offerings [5]

Core Viewpoint - The National Medical Insurance Drug List for 2025 and the first version of the Commercial Insurance Innovative Drug List were released in Guangzhou, highlighting the inclusion of various innovative treatments for serious conditions [1] Group 1: Drug Inclusion - The first version of the Commercial Insurance Innovative Drug List includes 19 drugs [1] - The list features CAR-T therapies for cancer treatment, as well as treatments for neuroblastoma, Gaucher disease, and Alzheimer's disease [1]

Core Points - The 2025 National Medical Insurance Drug List and the first version of the Commercial Insurance Innovative Drug List were released on December 7 in Guangzhou [3] - A total of 114 new drugs were added to the National Medical Insurance Drug List, with 50 being first-class innovative drugs, achieving an overall success rate of 88%, a significant increase from 76% in 2024 [3] - The new drug list includes medications for major diseases such as triple-negative breast cancer, pancreatic cancer, and lung cancer, as well as treatments for rare diseases and chronic conditions [3] Group 1 - The National Medical Insurance Drug List now includes a total of 3,253 drugs, comprising 1,857 Western medicines and 1,396 traditional Chinese medicines [3] - The inclusion of drugs in the Commercial Insurance Innovative Drug List includes 19 medications, such as CAR-T for cancer treatment and drugs for rare diseases like neuroblastoma and Gaucher disease [3] - The adjustment significantly enhances the coverage for key areas such as cancer, chronic diseases, mental health, rare diseases, and pediatric medications [3]

Core Viewpoint - The 2025 National Medical Insurance Drug List has successfully added 114 new drugs, including 50 innovative Class I drugs, with an overall success rate of 88%, significantly higher than the 76% in 2024 [1][5]. Group 1 - The 2025 National Medical Insurance Drug List includes drugs that fill gaps in basic medical insurance coverage, such as treatments for triple-negative breast cancer, pancreatic cancer, and lung cancer [5]. - The list also incorporates medications for rare diseases like Langerhans cell histiocytosis and thalassemia, as well as chronic diseases such as diabetes and autoimmune diseases [5]. - The total number of drugs in the National Medical Insurance Drug List has increased to 3,253, with 1,857 Western medicines and 1,396 traditional Chinese medicines, enhancing coverage in key areas like cancer, chronic diseases, mental health, rare diseases, and pediatric medications [5]. Group 2 - The first version of the commercial insurance innovative drug list includes 19 drugs, featuring CAR-T therapies for cancer treatment, medications for neuroblastoma and Gaucher disease, and treatments for Alzheimer's disease [5].